Renal Cell Carcinoma
RENAL CELL CARCINOMA ADVISOR
FEATURED CONTENT
-
The PFS benefit was driven primarily by patients with intermediate-risk disease.
-
Nivolumab plus ipilimumab did not prolong disease-free survival, and 43% of patients discontinued treatment due to toxicities.
-
A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
-
Cabozantinib can produce durable responses in patients with advanced MiT family translocation renal cell carcinoma, a new study suggests.
-
Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.
RENAL CELL CARCINOMA NEWS
Next post in Renal Cell Carcinoma
Loading...
Loading...